Centessa Pharmaceuticals plc Key Executives
This section highlights Centessa Pharmaceuticals plc's key executives, including their titles and compensation details.
Find Contacts at Centessa Pharmaceuticals plc
(Showing 0 of )
Centessa Pharmaceuticals plc Earnings
This section highlights Centessa Pharmaceuticals plc's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
$13.17
Stock Price
$1.75B
Market Cap
77
Employees
Altrincham, None
Location
Financial Statements
Access annual & quarterly financial statements for Centessa Pharmaceuticals plc, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $6.85M | $- | $- | $- |
| Cost of Revenue | $- | $- | $130.92K | $33.99K | $- |
| Gross Profit | $- | $6.85M | $-130.92K | $-33.99K | $- |
| Gross Profit Ratio | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $150.24M | $124.41M | $155.08M | $96.31M | $9.30M |
| General and Administrative Expenses | $50.81M | $53.73M | $55.20M | $43.01M | $1.14M |
| Selling and Marketing Expenses | $- | $- | $- | $42.93M | $- |
| Selling General and Administrative Expenses | $50.81M | $53.73M | $55.20M | $42.97M | $1.14M |
| Other Expenses | $- | $- | $2.34M | $- | $155.00K |
| Operating Expenses | $201.06M | $178.14M | $210.28M | $139.28M | $10.44M |
| Cost and Expenses | $- | $178.14M | $210.28M | $139.31M | $10.44M |
| Interest Income | $14.02M | $10.48M | $7.03K | $2.55K | $378 |
| Interest Expense | $-10.09M | $9.91M | $7.03M | $2.55M | $378.00K |
| Depreciation and Amortization | $- | $813.14K | $130.92K | $33.99K | $6.00K |
| EBITDA | $-201.06M | $-166.07M | $-212.26M | $-379.16M | $-10.43M |
| EBITDA Ratio | 0.00% | -2423.26% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-201.06M | $-171.28M | $-212.26M | $-139.31M | $-10.44M |
| Operating Income Ratio | 0.00% | -2499.39% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-31.86M | $-4.86M | $-4.69M | $-6.87M | $-223.00K |
| Income Before Tax | $-232.91M | $-176.14M | $-216.95M | $-381.74M | $-10.66M |
| Income Before Tax Ratio | 0.00% | -2570.28% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $2.84M | $-25.06M | $-747.00K | $113.99K | $378.00K |
| Net Income | $-235.76M | $-151.09M | $-216.21M | $-381.85M | $-11.04M |
| Net Income Ratio | 0.00% | -2204.65% | 0.00% | 0.00% | 0.00% |
| EPS | $-2.06 | $-1.57 | $-2.31 | $-4.24 | $-0.08 |
| EPS Diluted | $-2.06 | $-1.57 | $-2.31 | $-4.24 | $-0.08 |
| Weighted Average Shares Outstanding | 114.47M | 96.18M | 93.40M | 89.99M | 142.06M |
| Weighted Average Shares Outstanding Diluted | 114.47M | 96.18M | 93.40M | 89.99M | 142.06M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $6.91M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $236.26K | $239.86K | $248.14K | $236.62K | $237.76K | $89.81K | $36.27K | $34.70K | $31.72K | $27.84K | $12.01K | $12.94K | $- | $2.01K | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-236.26K | $-239.86K | $6.66M | $-236.62K | $-237.76K | $-89.81K | $-36.27K | $-34.70K | $-31.72K | $-27.84K | $-12.01K | $-12.94K | $- | $-2.01K | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 96.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $60.87M | $33.90M | $32.81M | $22.64M | $29.97M | $28.19M | $33.67M | $32.83M | $27.84M | $36.74M | $53.65M | $36.85M | $41.53M | $25.85M | $18.13M | $10.78M | $994.00K | $2.57M | $1.87M | $3.33M |
| General and Administrative Expenses | $13.71M | $12.50M | $11.16M | $13.44M | $12.31M | $12.02M | $13.35M | $16.05M | $13.77M | $12.28M | $14.76M | $14.38M | $12.99M | $12.46M | $11.84M | $5.72M | $308.00K | $193.00K | $258.00K | $383.00K |
| Selling and Marketing Expenses | $- | $- | $- | $-247.54K | $-141.01K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.52M | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $13.71M | $12.50M | $11.16M | $13.19M | $12.17M | $12.02M | $13.35M | $16.05M | $13.77M | $12.28M | $14.76M | $14.38M | $12.99M | $12.46M | $11.84M | $8.24M | $308.00K | $193.00K | $258.00K | $383.00K |
| Other Expenses | $- | $- | $- | $-1.54M | $-878.00K | $-1.68M | $-1.53M | $-1.35M | $-70.00K | $-3.14M | $5.36M | $196.00K | $235.00K | $-1.91M | $-191.00K | $- | $- | $- | $- | $- |
| Operating Expenses | $74.58M | $46.41M | $43.98M | $35.83M | $42.15M | $40.21M | $47.02M | $48.88M | $41.60M | $49.03M | $68.41M | $51.24M | $54.52M | $38.31M | $29.98M | $19.02M | $3.18M | $2.04M | $2.14M | $2.92M |
| Cost and Expenses | $74.58M | $46.41M | $43.98M | $36.07M | $42.40M | $40.21M | $47.02M | $48.88M | $41.60M | $49.03M | $68.41M | $51.24M | $54.52M | $38.31M | $29.98M | $19.02M | $3.18M | $2.04M | $2.14M | $2.92M |
| Interest Income | $4.84M | $3.34M | $3.24M | $2.59M | $2.93M | $2.95M | $2.06M | $2.53M | $2.16K | $77.00K | $25.00K | $104.00K | $- | $65.00K | $27.00K | $38.00K | $102.00K | $100.00K | $89.00K | $86.00K |
| Interest Expense | $2.48M | $2.56M | $2.52M | $2.53M | $2.57M | $2.54M | $2.45M | $2.35M | $2.16M | $1.84M | $1.63M | $1.40M | $1.27M | $65.00K | $27.00K | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $230.00K | $236.00K | $236.00K | $239.86K | $248.14K | $236.62K | $237.76K | $89.81K | $36.27K | $34.70K | $31.72K | $27.84K | $12.01K | $12.94K | $7.00K | $2.01K | $1.50K | $2.12M | $2.13M | $3.19M |
| EBITDA | $-107.57M | $-39.16M | $-40.40M | $-34.78M | $-33.16M | $-38.47M | $-46.40M | $-48.03M | $-41.95M | $-51.69M | $-62.47M | $-52.69M | $-58.21M | $-39.96M | $-41.29M | $-240.24M | $-3.00M | $-22.00K | $-99.00K | $181.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -509.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-74.58M | $-46.41M | $-43.98M | $-36.07M | $-35.48M | $-40.21M | $-47.02M | $-48.88M | $-41.60M | $-49.03M | $-68.41M | $-53.22M | $-58.29M | $-38.31M | $-41.29M | $-19.02M | $-3.00M | $-2.12M | $-2.13M | $-3.19M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -513.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-35.70M | $4.45M | $869.00K | $-1.48M | $-515.00K | $-1.26M | $-1.92M | $-1.16M | $-2.23M | $-4.99M | $3.73M | $-1.20M | $-2.37M | $-1.84M | $-164.00K | $-221.27M | $-281.00K | $-22.00K | $-99.00K | $181.00K |
| Income Before Tax | $-110.28M | $-41.96M | $-43.11M | $-37.54M | $-36.00M | $-41.47M | $-48.94M | $-50.04M | $-43.84M | $-54.02M | $-64.68M | $-54.42M | $-60.66M | $-40.16M | $-41.45M | $-240.29M | $-3.29M | $-2.14M | $-2.23M | $-3.01M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -520.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $1.05M | $608.00K | $705.00K | $480.73K | $1.15M | $-2.83M | $-24.05M | $677.00K | $-664.00K | $-141.00K | $-22.00K | $80.00K | $114.00K | $-65.00K | $-11.34M | $3 | $- | $-22.00K | $-99.00K | $181.00K |
| Net Income | $-111.33M | $-42.57M | $-43.82M | $-38.02M | $-37.16M | $-38.65M | $-24.89M | $-50.71M | $-43.17M | $-53.88M | $-64.66M | $-54.50M | $-60.77M | $-40.16M | $-41.45M | $-240.29M | $-3.29M | $-2.14M | $-2.23M | $-3.01M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -537.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.84 | $-0.37 | $-0.40 | $-0.38 | $-0.38 | $-0.40 | $-0.26 | $-0.53 | $-0.46 | $-0.57 | $-0.69 | $-0.60 | $-0.68 | $-0.45 | $-0.65 | $-2.75 | $-0.22 | $-0.02 | $0.00 | $0.00 |
| EPS Diluted | $-0.84 | $-0.37 | $-0.40 | $-0.38 | $-0.38 | $-0.40 | $-0.26 | $-0.53 | $-0.46 | $-0.57 | $-0.69 | $-0.60 | $-0.68 | $-0.45 | $-0.65 | $-2.75 | $-0.22 | $-0.02 | $0.00 | $0.00 |
| Weighted Average Shares Outstanding | 132.05M | 116.25M | 109.49M | 99.89M | 97.92M | 96.65M | 95.16M | 94.94M | 94.60M | 94.33M | 94.11M | 90.51M | 89.94M | 89.90M | 63.52M | 87.42M | 15.00M | 142.06M | - | - |
| Weighted Average Shares Outstanding Diluted | 132.05M | 116.25M | 109.49M | 99.89M | 97.92M | 96.65M | 95.16M | 94.94M | 94.60M | 94.33M | 94.11M | 90.51M | 89.94M | 89.90M | 63.52M | 87.42M | 15.00M | 142.06M | - | - |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $383.22M | $128.03M | $393.64M | $595.08M | $7.23M |
| Short Term Investments | $98.96M | $128.52M | $- | $- | $- |
| Cash and Short Term Investments | $482.18M | $256.55M | $393.64M | $595.08M | $7.23M |
| Net Receivables | $- | $39.15M | $26.72M | $16.81M | $- |
| Inventory | $- | $1 | $-29.99M | $-17.81M | $1.00M |
| Other Current Assets | $54.23M | $19.39M | $17.38M | $16.88M | $3.94M |
| Total Current Assets | $536.41M | $315.09M | $393.64M | $595.08M | $11.16M |
| Property Plant Equipment Net | $11.76M | $12.95M | $1.17M | $162.00K | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $26.59M | $29.65M | $3.51M | $- | $- |
| Other Non-Current Assets | $2.05M | $2.55M | $45.98M | $34.39M | $552.00K |
| Total Non-Current Assets | $40.39M | $45.15M | $50.66M | $34.55M | $552.00K |
| Other Assets | $- | $- | $- | $- | $-0 |
| Total Assets | $576.80M | $360.25M | $444.31M | $629.63M | $11.72M |
| Account Payables | $7.14M | $11.81M | $13.84M | $7.30M | $1.03M |
| Short Term Debt | $- | $- | $- | $- | $5.63M |
| Tax Payables | $835.00K | $112.00K | $1.58M | $769.00K | $- |
| Deferred Revenue | $- | $- | $- | $- | $1.04M |
| Other Current Liabilities | $50.02M | $27.46M | $22.92M | $16.57M | $1.96M |
| Total Current Liabilities | $58.00M | $39.38M | $38.34M | $24.64M | $8.62M |
| Long Term Debt | $8.29M | $84.59M | $69.80M | $75.70M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $108.97M | $29.00K | $- | $37.74M | $- |
| Total Non-Current Liabilities | $117.25M | $84.62M | $108.14M | $138.08M | $25.52M |
| Other Liabilities | $- | $- | $-38.34M | $-24.64M | $- |
| Total Liabilities | $175.25M | $124.00M | $108.14M | $138.08M | $34.14M |
| Preferred Stock | $- | $- | $- | $- | $44.00K |
| Common Stock | $359.00K | $273.00K | $265.00K | $252.00K | $21.00K |
| Retained Earnings | $-988.70M | $-752.95M | $-601.86M | $-385.65M | $-22.42M |
| Accumulated Other Comprehensive Income Loss | $4.21M | $1.49M | $-1.50M | $688.00K | $-86.00K |
| Other Total Stockholders Equity | $1.39B | $987.42M | $939.26M | $876.27M | $20.65M |
| Total Stockholders Equity | $401.55M | $236.24M | $336.17M | $491.55M | $-22.42M |
| Total Equity | $401.55M | $236.24M | $336.17M | $491.55M | $-22.42M |
| Total Liabilities and Stockholders Equity | $576.80M | $360.25M | $444.31M | $629.63M | $11.72M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $576.80M | $360.25M | $444.31M | $629.63M | $11.72M |
| Total Investments | $98.96M | $128.52M | $- | $- | $- |
| Total Debt | $8.29M | $84.59M | $69.80M | $75.70M | $5.63M |
| Net Debt | $-374.94M | $-43.44M | $-323.84M | $-519.38M | $-1.60M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $383.22M | $395.03M | $127.37M | $118.22M | $128.03M | $171.50M | $145.22M | $259.99M | $393.64M | $444.84M | $484.16M | $544.47M | $595.08M | $578.82M | $613.76M | $298.61M | $7.23M |
| Short Term Investments | $98.96M | $123.42M | $167.46M | $111.96M | $128.52M | $109.84M | $158.37M | $86.24M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $482.18M | $518.45M | $294.83M | $230.18M | $256.55M | $281.34M | $303.59M | $346.23M | $393.64M | $444.84M | $484.16M | $544.47M | $595.08M | $578.82M | $613.76M | $298.61M | $7.23M |
| Net Receivables | $45.30M | $40.04M | $46.99M | $37.17M | $39.15M | $30.39M | $28.42M | $23.39M | $26.72M | $21.71M | $21.80M | $23.14M | $16.81M | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $1 | $1 | $17.86M | $14.53M | $11.58M | $-29.99M | $9.15M | $12.39M | $12.47M | $-17.81M | $10.22M | $14.18M | $1.39M | $- |
| Other Current Assets | $8.94M | $9.87M | $13.68M | $17.12M | $3.27M | $20.72M | $18.40M | $14.71M | $17.38M | $10.44M | $13.54M | $13.59M | $16.88M | $32.83M | $29.92M | $15.02M | $3.94M |
| Total Current Assets | $536.41M | $568.36M | $355.50M | $284.48M | $315.09M | $332.45M | $350.41M | $384.33M | $393.64M | $476.99M | $519.50M | $581.20M | $595.08M | $611.64M | $643.68M | $313.64M | $11.16M |
| Property Plant Equipment Net | $11.76M | $12.06M | $12.37M | $12.65M | $12.95M | $13.23M | $13.49M | $13.49M | $1.17M | $552.00K | $905.00K | $374.00K | $162.00K | $114.00K | $75.00K | $45.00K | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $26.59M | $27.05M | $28.59M | $29.17M | $32.37M | $29.58M | $26.75M | $- | $3.51M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.05M | $2.23M | $2.38M | $1.88M | $2.55M | $2.10M | $2.27M | $6.04M | $45.98M | $1.81M | $648.00K | $619.00K | $34.39M | $448.00K | $- | $6.84M | $552.00K |
| Total Non-Current Assets | $40.39M | $41.35M | $43.34M | $43.70M | $47.88M | $44.91M | $42.51M | $19.53M | $50.66M | $2.37M | $1.55M | $993.00K | $34.55M | $562.00K | $75.00K | $6.88M | $552.00K |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $576.80M | $609.72M | $398.85M | $328.17M | $362.97M | $377.36M | $392.92M | $403.86M | $444.31M | $479.36M | $521.05M | $582.19M | $629.63M | $612.21M | $643.76M | $320.52M | $11.72M |
| Account Payables | $7.14M | $7.44M | $5.32M | $7.50M | $11.81M | $10.85M | $11.09M | $14.37M | $13.84M | $10.86M | $8.23M | $6.69M | $7.30M | $18.46M | $7.26M | $12.22M | $1.03M |
| Short Term Debt | $- | $577.00K | $552.00K | $528.00K | $- | $482.00K | $460.00K | $398.00K | $- | $- | $- | $- | $- | $- | $- | $- | $5.63M |
| Tax Payables | $835.00K | $- | $- | $- | $112.00K | $- | $- | $2.12M | $1.58M | $- | $- | $769.00K | $769.00K | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $23.46M | $21.82M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $50.02M | $18.39M | $20.88M | $19.41M | $27.46M | $23.62M | $22.32M | $12.80M | $22.92M | $27.33M | $25.34M | $19.74M | $16.57M | $10.69M | $16.92M | $6.76M | $1.96M |
| Total Current Liabilities | $58.00M | $26.41M | $26.75M | $27.43M | $39.38M | $34.95M | $33.87M | $29.69M | $38.34M | $38.19M | $33.57M | $27.19M | $24.64M | $29.14M | $24.18M | $18.98M | $8.62M |
| Long Term Debt | $117.23M | $84.14M | $85.10M | $85.54M | $84.59M | $83.02M | $82.45M | $80.91M | $69.80M | $68.20M | $67.40M | $74.80M | $75.70M | $- | $- | $291.00K | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $8.89M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $2.72M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $29.00K | $29.00K | $29.00K | $29.00K | $29.00K | $- | $- | $- | $- | $43.00K | $43.00K | $43.00K | $37.74M | $33.93M | $33.93M | $22.62M | $- |
| Total Non-Current Liabilities | $117.25M | $84.17M | $85.12M | $85.57M | $87.34M | $83.02M | $82.45M | $80.91M | $108.14M | $68.24M | $67.44M | $74.84M | $138.08M | $33.93M | $33.93M | $22.91M | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $-38.34M | $0 | $0 | $- | $-24.64M | $- | $- | $- | $- |
| Total Liabilities | $175.25M | $110.58M | $111.88M | $113.01M | $126.72M | $117.97M | $116.31M | $110.60M | $108.14M | $106.43M | $101.01M | $102.04M | $138.08M | $63.07M | $58.12M | $41.89M | $8.62M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $247.85M | $- |
| Common Stock | $359.00K | $357.00K | $309.00K | $277.00K | $273.00K | $271.00K | $266.00K | $266.00K | $265.00K | $263.00K | $263.00K | $262.00K | $252.00K | $252.00K | $252.00K | $133.00K | $25.55M |
| Retained Earnings | $-988.70M | $-877.37M | $-834.81M | $-790.99M | $-752.95M | $-716.11M | $-677.46M | $-652.57M | $-601.86M | $-558.69M | $-504.81M | $-440.15M | $-385.65M | $-324.88M | $-284.72M | $-243.27M | $-23.84M |
| Accumulated Other Comprehensive Income Loss | $4.21M | $2.10M | $1.59M | $1.62M | $1.49M | $779.00K | $946.00K | $-599.00K | $-1.50M | $-1.70M | $-1.14M | $-18.00K | $688.00K | $2.74M | $3.23M | $2.13M | $572.00K |
| Other Total Stockholders Equity | $1.39B | $1.37B | $1.12B | $1.00B | $987.42M | $974.45M | $952.85M | $946.17M | $939.26M | $933.04M | $925.73M | $920.06M | $876.27M | $871.02M | $866.89M | $271.80M | $825.00K |
| Total Stockholders Equity | $401.55M | $499.14M | $286.96M | $215.16M | $236.24M | $259.39M | $276.61M | $293.26M | $336.17M | $372.92M | $420.04M | $480.15M | $491.55M | $549.13M | $585.64M | $278.63M | $3.10M |
| Total Equity | $401.55M | $499.14M | $286.96M | $215.16M | $236.24M | $259.39M | $276.61M | $293.26M | $336.17M | $372.92M | $420.04M | $480.15M | $491.55M | $549.13M | $585.64M | $278.63M | $3.10M |
| Total Liabilities and Stockholders Equity | $576.80M | $609.72M | $398.85M | $328.17M | $362.97M | $377.36M | $392.92M | $403.86M | $444.31M | $479.36M | $521.05M | $582.19M | $629.63M | $612.21M | $643.76M | $320.52M | $11.72M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $576.80M | $609.72M | $398.85M | $328.17M | $362.97M | $377.36M | $392.92M | $403.86M | $444.31M | $479.36M | $521.05M | $582.19M | $629.63M | $612.21M | $643.76M | $320.52M | $11.72M |
| Total Investments | $98.96M | $123.42M | $167.46M | $111.96M | $128.52M | $109.84M | $158.37M | $86.24M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $117.23M | $84.72M | $85.65M | $86.07M | $84.59M | $83.50M | $82.91M | $81.31M | $69.80M | $68.20M | $67.40M | $74.80M | $75.70M | $- | $- | $291.00K | $5.63M |
| Net Debt | $-266.00M | $-310.31M | $-41.72M | $-32.15M | $-43.44M | $-88.00M | $-62.31M | $-178.68M | $-323.84M | $-376.64M | $-416.76M | $-469.67M | $-519.38M | $-578.82M | $-613.76M | $-298.32M | $-1.60M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-235.76M | $-151.09M | $-216.21M | $-381.85M | $-10.66M |
| Depreciation and Amortization | $942.00K | $810.00K | $131.00K | $33.99K | $- |
| Deferred Income Tax | $2.65M | $-26.63M | $-2.86M | $-6.80M | $- |
| Stock Based Compensation | $33.55M | $29.39M | $24.96M | $14.85M | $336.00K |
| Change in Working Capital | $22.10M | $-18.86M | $-2.83M | $-5.38M | $-489.00K |
| Accounts Receivables | $- | $- | $-11.70M | $-6.72M | $- |
| Inventory | $- | $- | $11.70M | $-4.16M | $- |
| Accounts Payables | $-4.58M | $-2.73M | $6.35M | $4.16M | $-49.00K |
| Other Working Capital | $26.69M | $-16.13M | $-9.18M | $1.34M | $-440.00K |
| Other Non Cash Items | $34.46M | $6.03M | $-3.75M | $257.85M | $186.00K |
| Net Cash Provided by Operating Activities | $-142.06M | $-160.34M | $-200.55M | $-136.14M | $-10.63M |
| Investments in Property Plant and Equipment | $-34.00K | $-169.00K | $-1.14M | $-185.98K | $- |
| Acquisitions Net | $- | $- | $- | $63.43M | $- |
| Purchases of Investments | $31.30M | $-264.91M | $- | $- | $- |
| Sales Maturities of Investments | $- | $138.07M | $- | $- | $- |
| Other Investing Activities | $- | $- | $206.00K | $-1 | $- |
| Net Cash Used for Investing Activities | $31.27M | $-127.00M | $-931.00K | $63.25M | $- |
| Debt Repayment | $-762.00K | $- | $- | $73.93M | $1.36M |
| Common Stock Issued | $359.61M | $20.81M | $717.56K | $586.44M | $10.08K |
| Common Stock Repurchased | $- | $- | $- | $-12.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $5.91M | $310.00K | $457.00K | $586.14M | $1.00K |
| Net Cash Used Provided by Financing Activities | $364.75M | $21.12M | $457.00K | $660.07M | $1.36M |
| Effect of Forex Changes on Cash | $1.23M | $615.00K | $-418.00K | $1.90M | $-75.00K |
| Net Change in Cash | $255.19M | $-265.61M | $-201.44M | $590.08M | $-9.34M |
| Cash at End of Period | $383.22M | $128.03M | $393.64M | $595.08M | $7.23M |
| Cash at Beginning of Period | $128.03M | $393.64M | $595.08M | $5.00M | $16.57M |
| Operating Cash Flow | $-142.06M | $-160.34M | $-200.55M | $-136.14M | $-10.63M |
| Capital Expenditure | $-34.00K | $-169.00K | $-1.14M | $-185.98K | $- |
| Free Cash Flow | $-142.09M | $-160.51M | $-201.68M | $-136.33M | $-10.63M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-111.33M | $-42.57M | $-43.82M | $-38.05M | $-37.16M | $-38.65M | $-24.89M | $-50.71M | $-43.17M | $-53.88M | $-64.66M | $-54.50M | $-60.91M | $-39.97M | $-41.37M | $-240.29M | $-3.29M | $-2.14M | $-2.23M | $-3.01M |
| Depreciation and Amortization | $230.00K | $236.00K | $236.00K | $240.00K | $248.14K | $238.00K | $237.00K | $89.00K | $36.00K | $35.00K | $32.00K | $28.00K | $12.01K | $12.94K | $7.00K | $2.01K | $- | $- | $- | $- |
| Deferred Income Tax | $398.00K | $1.25M | $567.00K | $434.00K | $-135.33K | $-2.89M | $-23.64M | $- | $-2.86M | $-135.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $8.33M | $8.45M | $8.61M | $8.15M | $7.43M | $7.56M | $7.21M | $7.19M | $6.62M | $7.03M | $5.60M | $5.72M | $4.76M | $4.13M | $3.23M | $2.73M | $91.00K | $29.00K | $90.00K | $63.00K |
| Change in Working Capital | $25.34M | $11.80M | $-5.89M | $-9.17M | $-3.45M | $-4.45M | $-5.66M | $-5.38M | $-14.04M | $7.06M | $6.50M | $-2.35M | $-1.94M | $-138.49K | $-6.98M | $3.68M | $-409.00K | $-245.00K | $366.00K | $-209.00K |
| Accounts Receivables | $-12.10M | $9.84M | $- | $1.21M | $-7.96M | $-2.33M | $-6.19M | $4.35M | $-3.94M | $-2.50M | $427.33K | $-5.70M | $3.48M | $-5.09M | $-3.26M | $-1.86M | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $1 | $2.33M | $6.19M | $-9.72M | $3.94M | $2.50M | $-427.33K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $143.00K | $1.71M | $-2.19M | $-4.25M | $590.06K | $83.00K | $-1.58M | $-1.81M | $2.60M | $3.13M | $1.84M | $-1.22M | $4.16M | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $37.30M | $255.00K | $-3.70M | $-6.13M | $3.93M | $-4.53M | $-4.08M | $1.81M | $-16.64M | $3.93M | $4.65M | $-1.12M | $-5.42M | $4.95M | $-3.72M | $5.54M | $-409.00K | $-245.00K | $366.00K | $-209.00K |
| Other Non Cash Items | $34.23M | $-570.00K | $-290.05K | $1.10M | $1.96M | $795.00K | $2.67M | $975.00K | $1.86M | $800.00K | $-7.35M | $1.08M | $3.09M | $11.89M | $17.75M | $225.80M | $323.00K | $459.00K | $-43.00K | $-482.00K |
| Net Cash Provided by Operating Activities | $-42.80M | $-21.39M | $-40.58M | $-37.29M | $-31.10M | $-37.39M | $-44.06M | $-47.84M | $-51.56M | $-39.09M | $-59.88M | $-50.02M | $-56.29M | $-33.32M | $-33.87M | $-12.67M | $-3.28M | $-1.90M | $-1.81M | $-3.64M |
| Investments in Property Plant and Equipment | $- | $-34.00K | $2 | $-0 | $-28.03K | $-43.00K | $-10.00K | $-88.00K | $-652.00K | $-16.00K | $-229.00K | $-240.00K | $-63.70K | $-48.23K | $-36.92K | $-37.13K | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $18.25M | $-86.63M | $- | $- | $- | $- | $- | $- | $-153.75K | $99.80K | $-285.81K | $63.77M | $- | $- | $- | $- |
| Purchases of Investments | $- | $146.83M | $-120.53M | $-20.00M | $-70.24M | $-37.50M | $-71.09M | $-86.25M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $25.00M | $45.00M | $65.13M | $36.76M | $51.98M | $86.63M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-146.83M | $-52.90K | $16.76M | $-18.25M | $86.25M | $-71.09M | $-86.25M | $206.00K | $- | $- | $- | $4.60M | $- | $-112.00K | $-4.48M | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $25.00M | $44.96M | $-55.46M | $16.76M | $-18.29M | $48.71M | $-71.10M | $-86.34M | $-446.00K | $-16.00K | $-229.00K | $-240.00K | $-217.44K | $51.57K | $-322.74K | $63.74M | $- | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $73.64M | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $-30.00K | $242.71M | $107.27M | $9.65M | $6.24M | $14.56M | $12.07K | $- | $95.03K | $219.98K | $69.46K | $333.08K | $-933.26K | $-776.37K | $345.42M | $242.73M | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $29 | $-19 | $-12.01K | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.99M | $3.27M | $-1.96M | $838.00K | $118.00K | $180.00K | $12.00K | $- | $89.00K | $224.00K | $70.00K | $74.00K | $295.68K | $-295.68K | $345.41M | $241.89M | $1.28M | $77.00K | $- | $- |
| Net Cash Used Provided by Financing Activities | $2.96M | $245.98M | $105.31M | $10.49M | $6.38M | $14.74M | $12.00K | $- | $89.00K | $224.00K | $70.00K | $74.00K | $73.00M | $-1.07M | $345.41M | $242.73M | $1.28M | $77.00K | $- | $- |
| Effect of Forex Changes on Cash | $3.03M | $-1.90M | $-120.00K | $219.00K | $-504.00K | $220.00K | $381.00K | $518.00K | $722.00K | $-438.00K | $-268.00K | $-434.00K | $-1.67M | $265.00K | $3.35M | $-44.00K | $355.00K | $491.00K | $-60.00K | $-861.00K |
| Net Change in Cash | $-11.80M | $267.65M | $9.15M | $-9.81M | $-43.47M | $26.28M | $-114.77M | $-133.66M | $-51.20M | $-39.32M | $-60.30M | $-50.62M | $16.27M | $-41.20M | $308.89M | $291.38M | $-1.64M | $-1.33M | $-1.88M | $-4.50M |
| Cash at End of Period | $383.22M | $395.03M | $127.37M | $118.22M | $128.03M | $171.50M | $145.22M | $259.99M | $393.64M | $444.84M | $484.16M | $544.47M | $595.08M | $578.82M | $613.76M | $298.61M | $7.23M | $8.87M | $10.20M | $12.07M |
| Cash at Beginning of Period | $395.03M | $127.37M | $118.22M | $128.03M | $171.50M | $145.22M | $259.99M | $393.64M | $444.84M | $484.16M | $544.47M | $595.08M | $578.82M | $620.02M | $304.87M | $7.23M | $8.87M | $10.20M | $12.07M | $16.57M |
| Operating Cash Flow | $-42.80M | $-21.39M | $-40.58M | $-37.29M | $-31.10M | $-37.39M | $-44.06M | $-47.84M | $-51.56M | $-39.09M | $-59.88M | $-50.02M | $-56.29M | $-33.32M | $-33.87M | $-12.67M | $-3.28M | $-1.90M | $-1.81M | $-3.64M |
| Capital Expenditure | $- | $-34.00K | $2 | $-0 | $-28.03K | $-43.00K | $-10.00K | $-88.00K | $-652.00K | $-16.00K | $-229.00K | $-240.00K | $-63.70K | $-48.23K | $-36.92K | $-37.13K | $- | $- | $- | $- |
| Free Cash Flow | $-42.80M | $-21.42M | $-40.58M | $-37.29M | $-31.13M | $-37.44M | $-44.07M | $-47.93M | $-52.22M | $-39.10M | $-60.11M | $-50.26M | $-56.35M | $-33.37M | $-33.90M | $-12.70M | $-3.28M | $-1.90M | $-1.81M | $-3.64M |
Centessa Pharmaceuticals plc Dividends
Explore Centessa Pharmaceuticals plc's dividend history, including dividend yield, payout ratio, and historical payments.
Centessa Pharmaceuticals plc News
Read the latest news about Centessa Pharmaceuticals plc, including recent articles, headlines, and updates.
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
BOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2024.
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial (CRYSTAL-1) in participants with NT1, NT2 and IH.
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.
Centessa: Shift In Focus With ORX750 Development Continues To Pay Off
Centessa Pharmaceuticals shelved its SerpinPC candidate, which was being used to treat patients with Hemophilia B; Established net savings of $200 million because of this move. Positive interim and final analysis obtained from phase 1 study, using ORX750 for acutely sleep-deprived healthy volunteers; Positive outcome in terms of MWT and KSS efficacy measures. Results from several cohorts of phase 2a study using ORX750 to treat patients with NT1, NT2 and IH expected in 2025.
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
BOSTON and LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an upsized underwritten public offering of 15,254,237 of American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $14.75 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about September 16, 2024, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 2,288,135 ADSs at the public offering price, less underwriting discounts and commissions.
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
BOSTON and LONDON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced positive interim data from an ongoing Phase 1 trial of its highly potent and selective orexin receptor 2 (OX2R) agonist, ORX750, in acutely sleep-deprived healthy volunteers. ORX750 showed clinically meaningful and statistically significant improvements in mean sleep latency at the first two doses evaluated (1.0 mg and 2.5 mg) in the Maintenance of Wakefulness Test (MWT) compared to placebo. More specifically, the 2.5 mg dose was shown to restore normative wakefulness2 with a mean sleep latency of 32 minutes as measured by the MWT. ORX750 was also shown to have a favorable safety and tolerability profile with no observations of frequently reported on-target adverse events (AEs) associated with other OX2R agonists, and no cases of hepatotoxicity or visual disturbances across all three dose levels tested (1.0 mg, 2.0 mg, and 2.5 mg), as of the data cutoff date.1 Based on the interim data, the Company plans to rapidly advance ORX750 into Phase 2 studies in patients with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) beginning in the fourth quarter of 2024.
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS) ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS)
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
BOSTON and LONDON, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Wednesday, September 4th at 1:05 PM ET.
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
BOSTON and LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today reported financial results and business highlights for the second quarter ended June 30, 2024.
Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 48.9% in Centessa Pharmaceuticals (CNTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024.
Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals (CNTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
BOSTON and LONDON, May 13, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today reported financial results and business highlights for the first quarter ended March 31, 2024.
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about April 26, 2024, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 1,621,621 ADSs at the public offering price, less underwriting discounts and commissions.
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) to initiate a Phase 1 first-in-human, clinical trial of ORX750 for the treatment of narcolepsy. ORX750 is an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 (NT1), with potential applicability to narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and other sleep-wake disorders with normal orexin levels.
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
BOSTON and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2023.
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
BOSTON & LONDON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced that data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia, will be presented during an oral presentation at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Frankfurt, Germany, today, February 9, 2024. The Company previously shared Part 5 results during a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
BOSTON and LONDON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Saurabh Saha MD PhD, Chief Executive Officer of Centessa, is scheduled to present at the conference on Wednesday, January 10, 2024, at 4:30 PM PST.
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
BOSTON and LONDON, Dec. 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia. The data were shared in a poster presentation at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10, 2023. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemophilia B, with or without inhibitors.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CNTA.